DYRK1A Regulates the Bidirectional Axonal Transport of APP in Human-Derived Neurons

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Defects in axonal transport are early indicators of neurodegenerative diseases like Alzheimer's disease.
• DYRK1A (Dual specificity tyrosine-phosphorylation regulated kinase 1A) is implicated in Down syndrome and Alzheimer's disease, suggesting its role in disease pathogenesis.
• The precise role of DYRK1A in the intracellular transport and delivery of amyloid precursor protein (APP) in human neurons is not well understood.

Purpose of the Study:

• To investigate whether DYRK1A regulates the intracellular transport and delivery of APP in human neurons.
• To elucidate the molecular mechanisms by which DYRK1A affects APP axonal transport and motor protein dynamics.

Main Methods:

• Proteomic analysis of human cerebral organoids treated with harmine (a DYRK1A inhibitor).
• Live imaging of APP axonal transport in human-derived neurons with pharmacological inhibition or genetic manipulation of DYRK1A.
• Single-particle tracking and analysis to quantify vesicle density, velocity, and motor configuration dynamics.

Main Results:

• DYRK1A inhibition (using harmine) reduced APP vesicle density and increased retrograde transport stochasticity.
• Pharmacological or genetic inhibition of DYRK1A altered motor configuration exchange, impacting APP vesicle transport dynamics.
• Overexpression of DYRK1A enhanced retrograde APP transport, increasing vesicle density and processivity.

Conclusions:

• DYRK1A activity differentially regulates the axonal transport and intracellular distribution of APP in human neurons.
• DYRK1A acts as a key modulator of the axonal transport machinery involved in APP trafficking.
• Targeting DYRK1A activity, particularly through inhibition, presents a potential therapeutic avenue for restoring APP axonal transport in Alzheimer's disease and Down syndrome.